Company profile for Serodus

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Serodus AS is developing a suite of compounds aimed at halting or delaying the progression of diabetic kidney disease (DKD) ? a major cause of morbidity and mortality among individuals with type 2 diabetes. Current therapies, including ACE inhibitors, ARBs, and SGLT2 inhibitors, effectively manage blood sugar or blood pressure but do not fully prevent kidney damage caused by chronic inflammation. Serodus is tackling this gap h...
Serodus AS is developing a suite of compounds aimed at halting or delaying the progression of diabetic kidney disease (DKD) ? a major cause of morbidity and mortality among individuals with type 2 diabetes. Current therapies, including ACE inhibitors, ARBs, and SGLT2 inhibitors, effectively manage blood sugar or blood pressure but do not fully prevent kidney damage caused by chronic inflammation. Serodus is tackling this gap head-on with two distinct modalities:

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Norway
Address
Address
Heia 8, N-0268 Oslo
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

AMWC Asia-TDAC

AMWC Asia-TDAC

Not Confirmed

envelop Contact Supplier

AMWC Asia-TDAC

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty